1. Identifying novel therapeutic agents using xenograft models of pediatric cancer

   • Raushan T. Kurmasheva
   • Peter J. Houghton

   Review Article 18 May 2016 Pages: 221 - 232

   

2. The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside

   • A. Zaniboni
   • V. Formica

   Review Article 18 April 2016 Pages: 233 - 244

   

3. Anti-VEGF and anti-EGFR agents open up new horizons changing the landscape for their associations

   • Gerard Milano

   Letter to the Editor Open access 16 June 2016 Pages: 245 - 245

4. Response from Drs. Formica/Zaniboni to Dr. Milano

   • V. Formica
   • A. Zaniboni

   Letter to the Editor 17 June 2016 Pages: 247 - 247

5. Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients

   • Ting Zou
   • Jiye Yin
   • Zhaoqian Liu

   Original Article 14 June 2016 Pages: 249 - 258

   

6. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors

   • Junning Cao
   • Jian Zhang
   • Jin Li

   Original Article 14 June 2016 Pages: 259 - 269

   

7. Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors

   • David C. Smith
   • John Powderly
   • Patricia LoRusso

   Original Article 16 June 2016 Pages: 271 - 280

   

8. Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer

   • Yutaka Fujiwara
   • Kenji Tamura
   • Noboru Yamamoto

   Original Article 16 June 2016 Pages: 281 - 288

   

9. A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer

   • Seiji Yoshitomi
   • Naruto Taira
   • Toshiharu Mitsuhashi

   Original Article 17 June 2016 Pages: 289 - 294

10. Cystatin C as a predictor factor in patients with renal cell carcinoma treated by everolimus

    • Lubomir Bodnar
    • Rafał Stec
    • Cezary Szczylik

    Original Article 20 June 2016 Pages: 295 - 304

    

11. Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma

    • Ayana Tomono
    • Kaori Ito
    • Shigeki Yamada

    Original Article Open access 20 June 2016 Pages: 305 - 312

    

12. Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma

    • Elliot Kahen
    • Diana Yu
    • Damon R. Reed

    Original Article Open access 20 June 2016 Pages: 313 - 323

    

13. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features

    • Jwa Hoon Kim
    • Inkeun Park
    • Jae Lyun Lee

    Original Article 21 June 2016 Pages: 325 - 332

    

14. High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

    • Lin Jiang
    • Wenchao Wang
    • Hong Yu

    Original Article 21 June 2016 Pages: 333 - 339

    

15. Population pharmacokinetics of bevacizumab in cancer patients with external validation

    • Kelong Han
    • Thomas Peyret
    • Jin Jin

    Original Article Open access 21 June 2016 Pages: 341 - 351

    

16. Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma

    • Vikram Gota
    • Ashwin Karanam
    • Hari Menon

    Original Article 21 June 2016 Pages: 353 - 359

    

17. TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

    • D. Ferraro
    • D. Goldstein
    • behalf of the the Australasian Gastro-Intestinal Trials Group

    Original Article 22 June 2016 Pages: 361 - 367

    

18. Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)

    • A. Matikas
    • Ν. Kentepozidis
    • on behalf of the HORG’s Lung Cancer Working Group

    Original Article 22 June 2016 Pages: 369 - 376

    

19. Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations

    • Kosuke Mizoguchi
    • Yoichi Nakamura
    • Hiroshi Mukae

    Original Article 23 June 2016 Pages: 377 - 382

    

20. A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer

    • Yusuke Okuma
    • Yukio Hosomi
    • Shinichiro Mikura

    Original Article 23 June 2016 Pages: 383 - 388

    

21. Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer

    • Tsuyoshi Hata
    • Toshihiro Kudo
    • Taroh Satoh

    Original Article 23 June 2016 Pages: 389 - 396

    

22. Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer

    • Toshi Takaoka
    • Tetsuo Kimura
    • Tetsuji Takayama

    Original Article 24 June 2016 Pages: 397 - 403

    

23. A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors

    • Klaus Mross
    • Heike Richly
    • Max E. Scheulen

    Original Article Open access 27 June 2016 Pages: 405 - 417

    

24. New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma

    • Cécile Teuma
    • Marie Perier-Muzet
    • Stéphane Dalle

    Original Article 01 July 2016 Pages: 419 - 426

    

25. Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib

    • Lisa H. Lam
    • Edmund V. Capparelli
    • Razelle Kurzrock

    Original Article 02 July 2016 Pages: 427 - 432

    

26. Lack of pharmacokinetic drug–drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors

    • Laura Q. M. Chow
    • David C. Smith
    • Ling Gao

    Original Article Open access 05 July 2016 Pages: 433 - 441